Company’s 36-month beta value is 2.34.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTPI is 6.12M, and currently, short sellers hold a 2.53% ratio of that floaft. The average trading volume of PTPI on June 17, 2024 was 520.50K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PTPI) stock’s latest price update
Petros Pharmaceuticals Inc (NASDAQ: PTPI) has experienced a decline in its stock price by -10.47 compared to its previous closing price of 0.46. However, the company has seen a fall of -13.80% in its stock price over the last five trading days. accesswire.com reported 2024-05-14 that Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Please see Important Safety Information and study design below NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the availability of all strengths of the Company’s prescription erectile dysfunction (ED) medication, STENDRA (avanafil) on the telehealth platform Lemonaid Health, Inc. Lemonaid Health is a subsidiary of 23andMe Holding Co. (Nasdaq: ME), and a leading telemedicine provider. “With Lemonaid’s nationwide distribution and industry leading track record of treating a significant number of ED patients across the country, we are excited to collaborate with Lemonaid Health in this expanded access initiative for STENDRA.
PTPI’s Market Performance
PTPI’s stock has fallen by -13.80% in the past week, with a monthly drop of -19.41% and a quarterly drop of -72.66%. The volatility ratio for the week is 13.44% while the volatility levels for the last 30 days are 12.24% for Petros Pharmaceuticals Inc The simple moving average for the last 20 days is -25.40% for PTPI’s stock, with a simple moving average of -67.67% for the last 200 days.
PTPI Trading at -36.53% from the 50-Day Moving Average
After a stumble in the market that brought PTPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.23% of loss for the given period.
Volatility was left at 12.24%, however, over the last 30 days, the volatility rate increased by 13.44%, as shares sank -24.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.45% lower at present.
During the last 5 trading sessions, PTPI fell by -13.80%, which changed the moving average for the period of 200-days by -84.78% in comparison to the 20-day moving average, which settled at $0.5503. In addition, Petros Pharmaceuticals Inc saw -70.53% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTPI
Current profitability levels for the company are sitting at:
- -3.46 for the present operating margin
- 0.7 for the gross margin
The net margin for Petros Pharmaceuticals Inc stands at -3.15. The total capital return value is set at -0.85. Equity return is now at value -91.54, with -33.16 for asset returns.
Based on Petros Pharmaceuticals Inc (PTPI), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -0.96. The debt to equity ratio resting at 0.82. The interest coverage ratio of the stock is -1468.02.
Currently, EBITDA for the company is -7.35 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of -0.03. The receivables turnover for the company is 2.4for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.60.
Conclusion
In a nutshell, Petros Pharmaceuticals Inc (PTPI) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
